Programme 2020

Programme

Thursday: November 12, 2020

18.30 - 20.00

Welcome Reception

Friday: November 13, 2020

07.30 - 08.00

Breakfast

08.00 - 08.10

Meeting Registration

08.10 - 08.15

Introduction & Meeting Objectives

08.15 - 10.15

Session I: New challenges in genomics Part 1: Current challenges in clinical genomics
Chairs: Lucy Godley & Ravindra Majeti

  • How to identify and counsel a patient with a suspected germline abn in practice: Lucy Godley
  • CHIP/ACUS in the general population: what we know and what we do with it: Koichi Takahashi
  • Genetics and epigenetics IDH mutations/biology: TBC

Discussion

e-break

  • How to use genomics for prognosis assessment in AML: Lars Bullinger
  • Big data and AI in AML: Torsten Haferlach
  • Novel Ab approaches for targeting leukemic stem cells: Ravindra Majeti

Discussion

10.15 - 10.30

Coffee break

10.30 - 12.15

Session 2: What is standard of care in AML in 2020?

  • Fit AML over 60yo: 7+3 or not?: Eunice Wang
  • Secondary AML: Jeff Lancet
  • Maintenance therapy with oral AZA-QUAZAR: Andrew Wei
  • Which patients should have allo transplant in 2020?: TBC

e-break

  • Unfit AML with IDH mutation – Venetoclax or IDHi?: Eytan Stein
  • Relapsed FLT3 mutant AML: Mark Levis
  • Post-SCT maintenance in AML: Betul Oran
  • DHODH inhibition in AML: David Sykes
  • MDM2 inhibition in R/R AML: Naval Daver

Discussion

12.15 - 13.15

Session 3: New clinical trial designs to accelerate drug development
Chairs: Richard Stone & Marina Konopleva

  • Novel therapeutic platforms: Mark Levis
  • Translating research into practice: Marina Konopleva
  • EFS or OS for frontline clinical trials in AML?: Richard Stone
  • Clinical trial designs centered on MRD as an eligibility criterion or study endpoint: Elihu Estey
  • Transplantation trial networks: TBC

Discussion

13.15 - 14.15

Lunch

14.15 - 16.00

Session 4: Novel treatment strategies in ALL
Chairs: Dieter Hoelzer & Sabina Chiaretti

  • Progress and lessons learned from pediatric ALL: Noelle Frey
  • Which patients with ALL should have a transplant in first CR?: Dieter Hoelzer 
  • How to improve MRD detection: ddPCR, NGS: Sabina Chiaretti

Discussion

e-break

  • Progress in treatment of AYA: Wendy Stock
  • Do we still need chemotherapy in Ph+ ALL?: Elias Jabbour
  • Innovation in the treatment of T-ALL: Daniel DeAngelo

16.00 - 17.30

Session 5: Can we truly integrate MRD measurement into AML clinical practice?
Chairs: Roland Walter & Marion Subklewe

  • CHIP mutations detectable at the time of response: Steven Chan
  • Single cell sequencing and clinical applicability in detection and therapy of AML: Koichi Takahashi
  • How can we apply MRD into clinical practice?: Chris Hourigan

Discussion

19.00

Dinner

Saturday: November 14, 2020

08.00 - 08.15

Breakfast

08.15 - 11.15

Session 6: Novel targets, combinations and treatments in AML

Part 1: What is the next AML blockbuster?
Chairs: Richard Stone & Marina Konopleva 

  • New FLT3 inhibitors and combinations: Mark Levis
  • Antibody-drug conjugates: Roland Walter
  • Anti-CD47: David Sallman / Ravindra Majeti

Discussion

 

Part 2: What do we know about drug resistance?
Chairs: Mark Levis & Andrew Wei

  • Resistance to IDHi: Stephane de Botton
  • Targeting resistance to Venetoclax based therapies: Andrew Wei
  • Resistance to FLT3 inhibitors: Alexander Perl
  • Epigenetic therapies: TBC

Discussion

 

11.15 - 13.00

Session 7: Immunotherapy in ALL
Chairs: Sabina Chiaretti & Daniel DeAngelo

  • Blinatumomab from relapse to front-line therapy: Daniel DeAngelo
  • Inotuzumab from relapse to front-line therapy: Elias Jabbour
  • Allogenic CAR-T: Claire Roddie
  • CAR-T in ALL: Bijal Shah

Discussion

13.00 - 13.45

Lunch

13.45 - 15.45

Session 8: Immunotherapeutics in AML

Part 1
Chairs: Marion Subklewe

  • Biomarkers of sensitivity and mechanisms of resistance to immune checkpoint therapies in AML: Naval Daver
  • Bispecifics/BiTes in AML: Marion Subklewe
  • T-cells in AML: function, distribution and therapeutic potential: Evan Lind


Part 2: CAR-T/cellular
Chairs: John DiPersio & David Sallman

  • Which CAR-T cell strategy in AML has the most promise/potential vs pitfalls: Saar Gill
  • Cell therapy development for myeloid diseases: balancing efficacy and toxicity: Marco Davilla
  • CYAD-01: David Sallman
  • CAR NKs and other constructs: John DiPersio

Discussion

15:45

Final Meeting Summary & Conclusions
iwAL Committee

logo

Location

Sheraton Tampa Riverwalk Hotel
200 North Ashley Drive, Tampa,
Florida, 33602 USA

© 2017 - 2020 World Health Communications Ltd / Brandcast Health

Media Partner:

Meeting Organizers: